What Reconcile Treats: Main Uses and Benefits

Reconcile (Fluoxetine) is primarily used in the veterinary behavioral domain to provide supportive therapy for dogs diagnosed with separation anxiety, a condition characterized by panic and distress upon owner absence. The medication is commonly used for chronic, moderate to severe manifestations where the patient exhibits profound emotional instability when left alone. The core use is to help manage symptom clusters that may become intense or disruptive.

This generally includes inappropriate elimination (house-soiling), excessive destructive chewing or digging, and prolonged incessant vocalization (barking, howling). The medication is applied to address these distressing behaviors that escalate temporarily when the owner is absent. Reconcile is commonly used as supportive assistance with behavior modification programs. The primary therapeutic benefit contributes to easing the overall symptom load and supports the patient's sense of stability when symptoms are more noticeable during routine periods of solitude.

---

Quick Fact: Relief for Separation-Driven Distress

Therapeutic Focus	Symptom Category	Benefit
Primary Indication	Separation Anxiety Disorder	Supports emotional stability
Symptom Management	Destructive Behaviors, Vocalization	Helps ease overall symptom burden
Clinical Context	Adjunct to Training	Assists with functional stability

Eligibility Map: Who Can and Cannot Use Reconcile

The official regulatory profile for Reconcile strictly defines the eligible population, with several non-negotiable restrictions and contraindications.

Category	Official Regulatory Statement
Populations for whom use is allowed	Use is established for dogs diagnosed with separation anxiety.
Populations for whom use is contraindicated	Humans (Explicitly designated as not for human use).
Populations for whom use is contraindicated	Dogs with epilepsy or a history of seizures, or with known hypersensitivity to fluoxetine or other SSRIs.
Eligibility-related restrictions	Must not be used concurrently with a Monoamine Oxidase Inhibitor (MAOI).
Age-related eligibility rules	Safety and effectiveness have not been established in dogs less than six months of age or weighing less than 8.8 pounds (4.0 kg).
Pregnancy and lactation eligibility status	Use is not recommended in breeding, pregnant, or lactating animals.
Populations for whom use is not recommended	Use is not recommended for the treatment of aggression.

---

Connection to the overall eligibility profile

Regulatory documents strictly define the eligible population as dogs that meet minimum age and weight criteria, while absolutely prohibiting use in humans and dogs with a history of seizures. This profile ensures that use remains entirely within the boundaries of the established regulatory approval for the product, with additional limitations for young, breeding, and pregnant animals.

Reconcile Interactions with other medicines and products

Reconcile (fluoxetine hydrochloride) is an SSRI (Selective Serotonin Reuptake Inhibitor) and can interact with various medications and products, often increasing the risk of adverse effects like Serotonin Syndrome or seizures. Inform your healthcare provider of all current medications, supplements, and over-the-counter products.

Contraindicated Combinations

Certain combinations are strictly contraindicated due to high risk of serious adverse reactions, including Serotonin Syndrome—a potentially life-threatening condition involving dangerously high serotonin levels.

Drug Class/Example	Potential Risk
Monoamine Oxidase Inhibitors (MAOIs) (e.g., selegiline, tranylcypromine)	Serotonin Syndrome (Contraindicated)
Pimozide, Thioridazine	Increased risk of serious heart rhythm abnormalities (QT prolongation)
Drugs that lower seizure threshold (e.g., certain phenothiazines)	Increased risk of seizures

Increased Caution and Monitoring

Use caution when combining Reconcile with other agents that increase serotonin, as this raises the risk of Serotonin Syndrome. Due to fluoxetine's long half-life, a washout period of at least five weeks is often required when switching to an MAOI or other interacting drugs.

Fluoxetine is also a potent inhibitor of the CYP2D6 liver enzyme, which can significantly increase the blood levels of other medications metabolized by this pathway. These include certain Tricyclic Antidepressants (TCAs) (e.g., amitriptyline), some antipsychotics, and some antiarrhythmics (e.g., flecainide). Additionally, co-administration with products that interfere with blood clotting, such as NSAIDs, aspirin, or warfarin, may increase the risk of bleeding.

Molecular Mechanism: Selective Serotonin Transporter Blockade

The foundational action of Fluoxetine is the selective inhibition of the Serotonin Transporter (SERT or 5-HTT) protein, which normally removes Serotonin (5-HT) from the synaptic cleft. By blocking this reuptake process, the drug immediately increases the concentration and duration of 5-HT signaling in the synapse. This core mechanism acts within the domain of monoamine neurotransmitter dynamics, initiating a chain of events necessary to modulate activity in the central nervous system (CNS).

---

Systemic Effect: Neurocircuit Adaption

The sustained elevation of Serotonin triggers a process of neuroadaptation in the brain. Over several weeks, key presynaptic 5-HT autoreceptors become less sensitive (desensitized), reducing the inhibitory feedback on 5-HT release. This systemic adjustment enhances 5-HT neurotransmission in CNS circuits governing limbic and cortical activity, which results in a modified signaling profile within targeted pathways. The full functional consequence is inherently delayed, a constraint arising because the required neuroadaptation limits the rate at which the mechanism reaches its steady state.

How to Use Reconcile

The administration of Reconcile (Fluoxetine Hydrochloride) follows specific, officially labeled instructions that govern its use in the veterinary behavioral domain. The medicine is intended solely for oral use in dogs and is administered as a chewable tablet.

---

Administration Protocol and Dosing

The medicine is given once daily, with the exact dose tied to the patient's body weight. The recommended dosage range is between 1 to 2 mg/kg of body weight. To ensure accurate dosing, the appropriate fixed-dose tablet strength (8 mg, 16 mg, 32 mg, or 64 mg) is selected based on the dog’s weight. The tablets may be administered with or without food.

Instruction Domain	Official Requirement
Route	Oral administration only.
Frequency	Administered once daily.
Dosing Rule	Weight-based dose of 1 to 2 mg/kg of body weight.

---

Use Context and Duration

Official use requires the medicine to be administered in conjunction with a professional behavior modification program. The medicine is approved for dogs and puppies 6 months of age or older and those weighing at least 4.0 kg. The treatment plan should be reassessed if no improvement is noted within 8 weeks.

If a dose is missed, pet owners should administer only the next scheduled dose at the regular time; official guidance states that doubling or increasing the dose is not permitted. Upon the decision to stop the medicine, no gradual dose tapering is necessary due to the product’s pharmacological profile.

---

Final Procedural Summary

The official instructions establish a standardized, once-daily oral dosing regimen that must be used alongside a mandatory behavior modification program. This protocol defines the precise method of administration, details the 8-week time frame for re-evaluation, and specifies the procedure for stopping treatment without tapering.

Research Evidence / Overview of Studies for Reconcile

Evidence for Use in Canine Separation Anxiety Disorder

The research was studied for Reconcile primarily using short-term, randomized, placebo-controlled clinical trials (RCTs). These studies were used in research exploring how the addition of the medication to a behavior modification plan might influence outcomes. The trials were applied in research contexts involving fluctuating or unstable symptoms of canine separation anxiety, such as destructive chewing, inappropriate elimination, and excessive vocalization, which are conditions characterized by fluctuating or episodic manifestations. The research specifically examined Reconcile in the context of being used as an adjunct to a formal behavior modification program, not as a standalone treatment. The studies monitored patient-reported outcomes describing perceived discomfort and overall severity scores as reported by dog owners over defined time intervals.

The findings describe patterns observed in the studies over the short-term follow-up periods (typically 4 to 8 weeks). Research highlights changes measured during the study period in the severity of separation anxiety symptoms in the group receiving the medication alongside training, compared to the group receiving a placebo alongside training. Studies monitored patterns related to the measured change in destructive chewing, house-soiling, and vocalization were observed in the group receiving the medication plus training. These studies report how symptoms evolved in the observed populations of client-owned dogs diagnosed with the disorder.

Studies Comparing Reconcile with Behavior Training Alone

Research examined the use of Reconcile specifically in comparison to a placebo, with all dogs in the main trials simultaneously receiving the standard of care—a behavior modification program. This research structure focused on differentiating the influence of adding Reconcile to the training regimen versus training alone.

Research examined the difference in overall symptom scores and outcomes related to specific behaviors (such as vocalization or destruction) between the two treatment groups over the defined study time. The data show patterns related to symptom measurement when the drug was evaluated in an adjunctive therapy setting.

Long-Term Evidence and Follow-up Duration in Studies

The most structured and comprehensive evidence for the medication was studied for is derived from short-term research exploring short-term symptom changes, primarily those lasting up to two months. These follow-up durations were sufficient to meet the regulatory requirements for approval for the specific use of separation anxiety.

While some limited data exists regarding the observation of dogs over longer periods (e.g., up to one year) related to safety, there is limited information for long-term outcomes regarding sustained observation of measured changes. Therefore, the long-term effects are not fully established, and evidence describing the durability of any observed changes in behavior beyond the initial trial period is restricted.

Key Studies & References

1. Fluoxetine: MedlinePlus Drug Information
2. Behavioral pharmacotherapy: a review of the role of fluoxetine in the treatment of canine separation anxiety

Common questions about Reconcile (FAQ)

---

Q: What are the long-term effects and risks of Reconcile?

Studies and official product information indicate that the trials for the effectiveness of Reconcile were primarily short-term, lasting up to 8 weeks. While a long-term laboratory safety study was conducted for up to one year, the effectiveness and clinical safety for use lasting more than 8 weeks have not been fully established. The official label information suggests that a professional veterinary assessment is needed for continued use beyond 8 weeks, considering that potential long-term adverse events seen in studies include weight loss and seizures.

---

Q: What do I do if my dog misses a dose of Reconcile?

Official regulatory guidance instructs that if a dose is missed, only the next scheduled dose is administered at the regular time. It is important to note that the dose is not increased or doubled to make up for the dose that was missed.

---

Q: How long does it take for Reconcile to start working for separation anxiety?

Clinical studies and official information indicate that some dogs may show initial improvement in symptoms of separation anxiety within the first week of starting Reconcile. However, the full beneficial effect of the medication may take up to 8 weeks to be fully observed, which is the time point used by veterinarians for re-evaluation of the treatment plan.

---

Q: What should I do if my dog accidentally eats more than the prescribed amount of Reconcile?

Regulatory product information states that if more than the prescribed amount is ingested, immediate contact with a veterinarian or animal poison control is necessary. Signs of overdose in dogs reported in studies can include incoordination, agitation, tremors, excessive drooling, and, in serious cases, seizures.

---

Q: Is it safe for a human to touch the Reconcile tablet or break it in half?

Regulatory documents state that Reconcile is for animal treatment only and must be kept out of the reach of children. The official label advises that in the event of accidental human ingestion, medical attention is required, as human overdose symptoms can include central nervous system effects like seizures or excessive sleepiness.

How to Store and Dispose of Reconcile (Fluoxetine)

Reconcile must be stored at controlled room temperature, specifically between 68 F and 77 F (20 C and 25 C). The product must be kept out of the reach of children.

Storage Conditions

Requirement	Specific Condition
Temperature Range	20 C to 25 C (Excursions up to 30 C are permitted.)
Container	Store in the original container and keep it tightly closed.
Protection	The medicine must be protected from moisture.

Disposal

Dispose of any unused or expired Reconcile according to local regulations for pharmaceutical waste. To prevent environmental contamination, the product should not be flushed down a toilet or sink unless specifically instructed by the official labeling.